In particular, several clinical trials investigated the efficacy of mAbs directed against cytotoxic T lymphocyte antigen-4 (CTLA- 4), or against PD-1 or its ligand (PD-L1) in HCC patients. The gene discussed is CD274; the disease is hepatocellular carcinoma.